Wednesday, March 14
2018 4:00 - 7:00 pm
Atara Biotherapeutics is a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Originating from over a decade of groundbreaking clinical experience at Memorial Sloan Kettering and QIMR Berghofer, Atara’s off-the-shelf, or allogeneic, T-cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment.
Location: Atara Biotherapeutics, Inc.
2430 Conejo Spectrum Street, Thousand Oaks, CA 91320
Host and Program Managers:
Chad Headlee, Associate Director Plant Engineering, Atara Biotherapeutics, Inc.
David Arellano, Project Manager, MEP/P Coordinator, DPR Construction
Merritt Postma, Director, Western Region, SKAN US
Joe Newell, Executive VP/Chief Technical Operations Officer, Atara Biotherapeutics, Inc.
Michael May, Senior Director, Plant Manager, Atara Biotherapeutics, Inc.
David Frey, Senior Director, CMC Cell Therapy, Atara Biotherapeutics, Inc.
Be sure to bring your photo ID with you, it will be required for security check in.